BioSpace News Archive

Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share.

Ibere Pharmaceuticals (the “Company”) announced today that it closed its initial public offering of 13,800,000 units at $10.00 per unit, which included the exercise in full of the underwriter’s over-allotment option to purchase 1,800,000 Units.

Haemonetics Corporation (“Haemonetics”) (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933,

ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka).

Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm.

Enzymatic synthesis to replace cumbersome chemical synthesis technology that requires hazardous chemicals and extensive post-synthesis processing

Amplifon is proud to celebrate World Hearing Day, confirming its commitment to the treatment and prevention of hearing loss, a condition that impacts nearly 40 million Americans.

CHOP/Penn study shows T cell activation in children with MIS-C more similar to adults with severe COVID-19

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that members of management will be participating in two upcoming virtual investor conferences.